National Institutes of Health

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Metabolon, Inc. is a health technology company specializing in metabolomics, which focuses on the analysis of metabolites to aid in disease detection and precision medicine. The company develops a range of clinical diagnostic tests, including QUANTOSE IR for early-stage insulin resistance and Meta IMD for identifying metabolites linked to inherited metabolic disorders. Metabolon also offers customizable research services and multiomics solutions, enabling academic and commercial researchers to explore various life sciences areas effectively. The company's technologies address a wide array of health conditions, including cardiovascular issues, diabetes, and cancer, and are utilized across sectors such as biotechnology, pharmaceuticals, and nutrition. Founded in 2000 and headquartered in Morrisville, North Carolina, Metabolon has a global presence, including offices in Munich, London, Madrid, and China, and maintains strategic partnerships with major firms in the pharmaceutical and consumer health industries.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.

Satio brings a dried blood spot and whole blood collection to the consumer; simple, painless, and clean using patches.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Morehouse School of Medicine, located in Atlanta, Georgia, is a historically Black college and university (HBCU) dedicated to training healthcare professionals, with a special emphasis on minority students. The institution offers a medical degree program along with master’s degrees in various fields, including Public Health and Biomedical Sciences. Medical students can specialize in areas such as Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry, and Surgery, completing clinical assignments at affiliated hospitals. The school is also engaged in research, focusing on cardiovascular studies, neuroscience, and health disparities. To support its mission, Morehouse manages an endowment fund, the earnings of which are utilized for scholarships, research funding, and academic programs. Admissions requirements vary by program, and the school provides scholarships aimed at supporting disadvantaged students, alongside academic and merit-based financial aid.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

University of Oklahoma Health Sciences Center, as a comprehensive academic health center, is to educate students, residents, and other trainees in professional and graduate programs to become Oklahoma’s future team of healthcare leaders, clinicians, researchers, and educators; to advance distinctive basic, translational, clinical, and population research; to innovate and commercialize discoveries; and to deliver exceptional patient care across the full breadth of adult, women’s, and children’s specialties.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Montefiore Health System offers advanced specialty programs, cardiology, and cardiac surgery. They provide cancer care, children’s health, tissue, and organ transplantation. Their services include women’s health, surgery, and surgical subspecialties. If anyone wants to contact them please contact them via phone call or email.

Medcognetics specializes in developing advanced artificial intelligence software aimed at enhancing the accuracy and efficiency of radiology workflows. Their platform allows radiologists to prioritize mammography patients based on ambiguous results, thereby facilitating early detection of breast cancer. By leveraging AI and machine learning, Medcognetics' technology offers a comprehensive overview of processed case images, pinpointing the locations of any abnormalities. This innovative approach aims to reduce breast cancer mortality by enabling timely intervention and treatment for patients.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Case Western Reserve University, located in Cleveland's University Circle, is an independent research institution established in 1843. It encompasses various schools and colleges, including the School of Medicine, School of Law, Case School of Engineering, College of Arts and Sciences, Frances Payne Bolton School of Nursing, Mandel School of Applied Social Sciences, School of Dental Medicine, and Weatherhead School of Management. The university is known for its excellence in medical education and biomedical research, with the School of Medicine recognized for its contributions to medical discoveries and training future physicians. The School of Law offers nationally ranked programs in international law, health law, and intellectual property law, integrating leadership courses and practical experiences into its curriculum. Case Western Reserve University is a member of the Association of American Universities and maintains full accreditation from the Higher Learning Commission, reflecting its commitment to educational quality and research excellence.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Coprata is a digital health and technology company that offers innovative solutions for monitoring gut health through stool analysis and artificial intelligence. By enabling hands-free stool sampling and automated monitoring of bowel movements during regular toilet use, Coprata provides individuals with valuable insights into their gut health. This service allows users to track the effects of their lifestyle choices and receive early warnings about potential changes in their gut health. The platform aims to facilitate the detection and management of both acute and chronic gastrointestinal diseases, as well as infectious diseases. Additionally, Coprata is focused on developing non-invasive methods for health monitoring that seamlessly integrate into daily routines, ultimately enhancing personalized wellness and health management.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Arkana Laboratories offers renal pathology, neuropathology and testing, apol1, and biopharmaceutical services. It is a provider of esoteric pathologic services and a centre for pathology focused on improving care for patients. For inquiries, email, telephone numbers, and physical addresses are available on their website.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

RAE Health is a mental health solutions company that bridges the gap between mobile health and digital therapeutics.

PETcoil, founded in 2018, is a company focused on enhancing healthcare through innovative medical imaging technology. Originating from research at Stanford University, the company has developed a groundbreaking radiofrequency-penetrable PET insert system that allows for simultaneous PET and MRI imaging. This patented portable PET scanner can be integrated into existing MRI machines, providing clinicians with the ability to obtain more precise and detailed images of patients' bodies. PETcoil's mission is to create affordable, high-performance molecular imaging systems that facilitate early and accurate disease diagnosis, making multi-modality medical imaging accessible to all patients in need.

Bringing together decades of research on neurological diseases, artificial intelligence (AI), neuroscience, speech analytics, speech pathology, and mobile software platforms for health monitoring, Aural Analytics has built proprietary metrics that use speech to capture changes in neurological health. With Aural Analytics’ downloadable apps, any smartphone or tablet becomes a powerful brain health monitor. This technology augments traditional functional rating scales commonly used to measure neurological health in clinical trials with objective, interpretable, and continuous outcomes. In turn, this results in more reliable and higher resolution outcomes for evaluating the effectiveness of drugs or other interventions. Aural Analytics’ technology can reveal the incremental changes that occur as a patient progresses from one point on a functional rating scale to the next.

Reliant Glycosciences is a biotechnology company focused on developing diagnostic and prognostic tools for patients with IgA nephropathy.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing patient care and early disease intervention. Founded in 2018, Dascena focuses on creating algorithmic software that processes electronic health record data to predict critical conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging extensive clinical research, the company provides tools that support clinical decision-making, facilitate point-of-care diagnostics, and serve as biopharma companion diagnostics. Dascena's innovations address significant unmet healthcare needs, ultimately aiming to improve care outcomes and save lives through timely and accurate interventions.

Enspectra Health, based in Mountain View, California, specializes in developing advanced imaging systems for medical applications. The company has created the first hand-held multiphoton imager for human use, enabling real-time imaging of live cellular anatomy beneath the skin. Its innovative device combines reflectance confocal and multiphoton laser scanning microscopy to produce multispectral images that reveal details not visible to the naked eye. This technology aids researchers and dermatologists in examining the structure and function of various tissues, including muscle, tendon, cartilage, and skin, thereby enhancing the diagnosis and treatment of skin conditions, particularly skin cancers. Enspectra Health aims to simplify the evaluation process for physicians and improve patient outcomes through its cutting-edge imaging solutions.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

HQ Science is a biotechnology company at the forefront of molecular diagnostics innovation.

Anavasi Diagnostics is a medical technology company that focuses on the development of molecular diagnostic testing.

Viora Health is a health and wellness company focused on advancing health equity among diverse populations. It offers tech-enabled, human-centered programs that utilize social and behavioral engagement to enhance capacity, satisfaction, outcomes, and revenue for healthcare providers. The company is backed by funding from reputable organizations such as the American Heart Association, the National Institutes of Health, Johnson and Johnson, and the National Science Foundation, with its initiatives validated through an Institutional Review Board-approved study. Viora Health's programs have demonstrated a 75% satisfaction score, double retention rates, and improved health outcomes, including reduced stress and better access to food and social support. Additionally, Viora Health develops a healthcare compliance platform aimed at enhancing adherence to diabetes prevention initiatives by connecting patients to programs, tracking data, and facilitating online engagement tools, which help diabetes prevention programs comply with insurance requirements and achieve outcome-based reimbursement.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

A biomarker test to diagnose a common and life-threatening bowel disease in preterm infants. It offers more accurate results than current options and allows earlier medical intervention.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

The Nemours Foundation is a non-profit organization established in 1936 and headquartered in Jacksonville, Florida. Its mission is to enhance the health and well-being of children globally by providing high-quality care and programs that are often not readily accessible, regardless of a family's financial situation. The foundation focuses on leadership and innovative services aimed at restoring and improving children's health. Its assets are managed by a board of directors, ensuring a commitment to excellence and distinction in all initiatives. Through its various programs and services, the Nemours Foundation strives to make a significant impact on pediatric health.

Phrase Health help hospitals monitor and analyze the information they provide to doctors and nurses at the point of care.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company focuses on creating pumpless platforms that utilize serum-free cellular mediums to facilitate communication between multi-organ systems. Their innovative technology incorporates integrated computational pharmacokinetics and pharmacodynamics modeling, allowing for live physiological response assessments through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as the liver and pancreas. This approach enables clients to predict in vivo functions without relying on animal models, advancing the field of biomedical research.

ID Genomics specializes in nucleotide sequence-based molecular diagnostics and epidemiologic analysis of microbial pathogens. We provide fast, high-resolution, large- or small-scale clonal identification for clinical microbiology, reference and academic research laboratories, using expanded multi-locus sequence typing (MLST), genome-wide polymorphism annotation, customized phylogenetic and genomic analysis and database creation.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Enspectra Health, based in Mountain View, California, specializes in developing advanced imaging systems for medical applications. The company has created the first hand-held multiphoton imager for human use, enabling real-time imaging of live cellular anatomy beneath the skin. Its innovative device combines reflectance confocal and multiphoton laser scanning microscopy to produce multispectral images that reveal details not visible to the naked eye. This technology aids researchers and dermatologists in examining the structure and function of various tissues, including muscle, tendon, cartilage, and skin, thereby enhancing the diagnosis and treatment of skin conditions, particularly skin cancers. Enspectra Health aims to simplify the evaluation process for physicians and improve patient outcomes through its cutting-edge imaging solutions.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

MRIMath specializes in medical imaging technology aimed at improving cancer diagnosis and treatment. The company develops solutions that assist oncologists and surgeons in identifying tumors and assessing treatment responses, thereby enhancing patient outcomes in oncology. MRIMath's innovative approach incorporates an interactive human-AI interface that offers a reliable and cost-effective tool for medical practitioners to monitor brain tumor growth. Beyond its imaging technology, MRIMath also provides hospital care, medical device services, and AI consulting, along with AI-powered software designed to streamline healthcare processes.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Photonic Pharma is an early phase of drug development which uses a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, notably the TOMi Scope. This handheld device employs advanced light-based technology, specifically near-infrared light waves, to create 3D images of the middle ear by seeing through the eardrum. This capability allows physicians to visualize the middle ear directly and safely, enabling them to assess its condition quickly and accurately. By determining the contents of the middle ear, clinicians can make informed decisions regarding the need for antibiotics or surgical interventions. PhotoniCare's technology not only addresses otology but also presents potential for growth in other medical fields.

A forensic toxicology and healthcare sciences laboratory with programs for all categories that include professional and amateur sports, pain management physicians, medical examiners, businesses and obstetricians, the science that makes what we do possible is unsurpassed.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Mesa Biotech simplifies DNA testing. The Mesa Biotech team has achieved a dramatic simplification in the complexity of DNA and RNA molecular testing. Mesa Biotech is based in sunny San Diego, California with a satellite testing laboratory in Santa Fe, New Mexico.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

AventuSoft is a pioneer in biologically inspired solutions! Our mission, is to continuously enhance the efficiency and function of people through advanced biologically inspired engineering. The human auditory system is an existence proof for accurate speech processing and has solved the principal complexities that currently plague speech processing solutions: multiple sources, noisy environments, and mismatched test/train data. Solutions by AventuSoft, are developed by applying in-depth knowledge of psychoacoustics, biological signals, and novel signal processing techniques to leverage the benefits seen in human system.

PETcoil, founded in 2018, is a company focused on enhancing healthcare through innovative medical imaging technology. Originating from research at Stanford University, the company has developed a groundbreaking radiofrequency-penetrable PET insert system that allows for simultaneous PET and MRI imaging. This patented portable PET scanner can be integrated into existing MRI machines, providing clinicians with the ability to obtain more precise and detailed images of patients' bodies. PETcoil's mission is to create affordable, high-performance molecular imaging systems that facilitate early and accurate disease diagnosis, making multi-modality medical imaging accessible to all patients in need.

Lohocla is a research and development company that is at the forefront of discovery bioscience center photoof medications for chronic pain, addictive and other mental health and neurological disorders. Lohocla is also unique in its dedication to developing biological markers (diagnostics) that aid the physician in properly allocating Lohocla-developed medications to the appropriate patients. The tenets of personalized medicine drive the company’s research efforts.

Cicero Diagnostics is a women’s healthcare diagnostic company. It is dedicated to the advancement of clinical assays for understudied women’s diseases primarily in the area of infertility. Its current testing platforms, under the brand ReceptivaDx™ , include several biomarkers highly associated with inflammation on the uterine lining most often diagnosed as endometriosis.

Enable Biosciences is a biotechnology company focused on developing ultrasensitive tests for various diseases, including HIV and type 1 diabetes. The company creates advanced immunoassays that allow for the early detection and treatment of autoimmune and infectious diseases. By providing sensitive antibody detection, Enable Biosciences aims to facilitate early diagnosis and precise monitoring of challenging conditions, such as Lyme disease, ultimately improving patient outcomes through timely intervention.

Fluxion Biosciences develops analytical instruments for functional cellular analyses, targeting applications in life sciences, drug discovery, and diagnostics. The company offers a range of products, including the IsoFlux Liquid Biopsy System, which enriches rare cell populations such as circulating tumor cells, and various enrichment and downstream analysis kits. Additionally, Fluxion provides BioFlux systems for live cell analysis under shear flow, catering to fields like immunology and cancer research, as well as IonFlux systems for automated patch clamping. Founded in 2005 and based in Alameda, California, Fluxion also offers analytical services for circulating tumor cell and liquid biopsy applications, serving biotechnology and pharmaceutical companies, academic institutions, and government research organizations through a global network of distributors.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company focuses on creating pumpless platforms that utilize serum-free cellular mediums to facilitate communication between multi-organ systems. Their innovative technology incorporates integrated computational pharmacokinetics and pharmacodynamics modeling, allowing for live physiological response assessments through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as the liver and pancreas. This approach enables clients to predict in vivo functions without relying on animal models, advancing the field of biomedical research.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

Photonic Pharma is an early phase of drug development which uses a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells.

The Wistar Institute is the first independent institution in the United States dedicated to medical research and training, recognized for its significant contributions to biomedical science. Originally established as an anatomical teaching museum, it has transformed into a leading center for basic biomedical research and was designated a National Cancer Institute Cancer Center in 1972. The institute specializes in research areas including immunology, infectious diseases, and vaccine development. Its groundbreaking discoveries have facilitated the creation of vaccines for diseases such as rabies, rubella, and rotavirus, as well as the identification of genes linked to various cancers, including breast, lung, and prostate cancer. Additionally, Wistar has played a crucial role in advancing monoclonal antibodies and other vital research technologies, fostering a collaborative environment aimed at addressing critical health challenges.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

Intake Health is a developer of a continuous passive health monitoring device that operates at home without requiring changes in user behavior. The device is designed to be mounted on a toilet, where it automatically tests urine from flush water to deliver lab-quality results for various health and dietary indicators. By leveraging advanced biosensors and wireless technology, the system accurately tracks hydration and nutrition by quantifying specific urinary biomarkers. Users receive instant insights on their health metrics through a mobile application, facilitating informed decision-making regarding their well-being. Intake Health aims to enhance health predictions and personalized prevention strategies through the accumulation of personalized biomarkers over time. The company has received funding from the National Science Foundation and the National Institutes of Health.

Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

West Virginia University School of Medicine is dedicated to education, research, clinical care, and community service. It equips students with comprehensive medical training and promotes advancements in healthcare through innovative research. The institution features advanced medical technologies such as magnetic resonance imaging, lithotripsy, and laser surgery, which enhance both teaching and patient care. By integrating these technologies into its curriculum and services, the school aims to improve health outcomes and contribute to the overall well-being of individuals and communities.

The University of Chicago Medicine is an academic medical institution that operates as a hospital which provides healthcare services. In addition, it provides medical education. The University of Chicago Medicine is comprised of the University of Chicago Pritzker School of Medicine; University of Chicago Biological Sciences Division; and University of Chicago Medical Center. The institution’s physicians are members of the University of Chicago Physicians Group which includes about 900 physicians and covers the full array of medical and surgical specialties. Its physicians are faculty members of the Pritzker School of Medicine. The University of Chicago Medicine was founded in 1927 and is based in Chicago, Illinois.

SOFIE focuses on advancing the field of theranostics by simplifying the adoption and application of molecular imaging and radiopharmaceuticals. The company offers a comprehensive range of imaging and radiochemistry systems, along with a robust network of radiopharmacies and contract manufacturing services to provide novel diagnostic and therapeutic agents. By developing molecular imaging probes and devices, SOFIE enables physicians to identify tumors that are responsive to targeted therapies, thereby facilitating personalized healthcare and informed treatment decisions. The company's commitment to reducing the cost and complexity of these technologies aims to enhance patient health outcomes.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Quadrant Biosciences Inc. is a life sciences company focused on developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges, particularly in the early identification of neurological disorders such as Autism Spectrum Disorder, concussion, and Parkinson's Disease. Founded in 2015 and based in Syracuse, New York, the company has established collaborative research relationships with various institutions to explore innovative diagnostic and therapeutic solutions. Quadrant Biosciences leverages its expertise in RNA analysis to enhance healthcare delivery and has also contributed to addressing health issues related to the COVID-19 pandemic. The company aims to improve lives through its commitment to advancing molecular diagnostic tools.

NeuraMedica is a medical device company focused on developing an innovative bioabsorbable surgical clip aimed at closing the dura mater. This advanced product enables neurosurgeons and orthopedic spine surgeons to achieve a secure dural closure much faster than traditional methods. By streamlining the procedure, NeuraMedica's solution not only reduces the duration of anesthesia but also contributes to significant cost savings for healthcare providers. The company’s technology promotes better patient outcomes, making it a valuable addition to surgical practices in neurosurgery and orthopedic spine surgery.

Enable Biosciences is a biotechnology company focused on developing ultrasensitive tests for various diseases, including HIV and type 1 diabetes. The company creates advanced immunoassays that allow for the early detection and treatment of autoimmune and infectious diseases. By providing sensitive antibody detection, Enable Biosciences aims to facilitate early diagnosis and precise monitoring of challenging conditions, such as Lyme disease, ultimately improving patient outcomes through timely intervention.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

SEngine Precision Medicine, Inc. is a Seattle-based company that specializes in personalized cancer treatments through innovative technology. Founded in 2015, the company utilizes a proprietary search engine that combines functional genomics with robotic testing of cancer drugs on live patient organoids. This approach allows for the simultaneous testing of over 200 drugs against a patient’s unique tumor organoid, providing insights into the most effective and least toxic treatment options that traditional DNA sequencing may not reveal. By leveraging anonymized test results, SEngine not only empowers patients and oncologists with tailored treatment options but also aids in the development of new cancer-fighting drugs, positioning itself as a leader in the next generation of oncology diagnostics.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Modulim is a leader in light-based imaging technology focused on tissue and vascular assessment through spatial frequency domain imaging (SFDI). The company has developed the Clarifi Imaging System, which aids clinicians in identifying patients at risk for complications such as diabetic foot ulcers and amputations due to compromised circulation. By enabling timely interventions, this technology plays a crucial role in preserving patients' limbs and lives. Additionally, Modulim's devices are applicable in research, aesthetics, and medicine, providing professionals with transformative tools for the prevention, diagnosis, and treatment of various medical skin conditions.

Blackfynn is a technology-driven life sciences company focused on transforming the diagnosis and treatment of neurological diseases. The company has developed a data management platform that addresses significant barriers in neuroscience by integrating various types of data, including EEG, radiology, genomics, and clinical information. This platform provides a comprehensive set of APIs and data libraries that facilitate the visualization and analysis of neurological data in real-time, allowing medical professionals to enhance their understanding of conditions such as epilepsy, Alzheimer's disease, and Parkinson's disease. By streamlining existing workflows and enabling the analysis of data from medical devices, Blackfynn aims to improve patient care and device performance in the field of neurology.